Collegium Pharmaceutical (STU:354) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:354 Collegium Pharmaceutical Inc STU:354
69 GF Score
Price €19.80
GF Value €41.34
! 4 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Collegium Pharmaceutical  (STU:354) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Collegium Pharmaceutical Cyclically Adjusted PS Ratio Related Terms


Collegium Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Collegium Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical Cyclically Adjusted PS Ratio Chart

Collegium Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.18 3.61 3.20 4.29

Collegium Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.49 2.83 3.98 2.64 2.84

STU:354 vs AMPH, IRWD, TLRY: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


STU:354
69GF Score
Collegium Pharmaceutical Inc STU:354
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Collegium Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Collegium Pharmaceutical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.296/333.9520*333.9520
=5.296

Current CPI (Jun. 2026) = 333.9520.

Collegium Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.016 241.428 0.022
201612 0.045 241.432 0.062
201703 0.069 243.801 0.095
201706 0.110 244.955 0.150
201709 0.342 246.819 0.463
201712 0.282 246.524 0.382
201803 1.576 249.554 2.109
201806 1.860 251.989 2.465
201809 1.828 252.439 2.418
201812 1.906 251.233 2.534
201903 1.969 254.202 2.587
201906 2.000 256.143 2.608
201909 1.959 256.759 2.548
201912 1.995 256.974 2.593
202003 1.980 258.115 2.562
202006 2.020 257.797 2.617
202009 1.933 260.280 2.480
202012 1.806 260.474 2.315
202103 1.769 264.877 2.230
202106 1.668 271.696 2.050
202109 1.844 274.310 2.245
202112 0.702 278.802 0.841
202203 2.217 287.504 2.575
202206 3.410 296.311 3.843
202209 3.647 296.808 4.103
202212 3.786 296.797 4.260
202303 3.931 301.836 4.349
202306 2.906 305.109 3.181
202309 2.988 307.789 3.242
202312 3.374 306.746 3.673
202403 3.222 312.332 3.445
202406 3.341 314.175 3.551
202409 3.611 315.301 3.825
202412 4.253 315.605 4.500
202503 5.143 319.799 5.371
202506 4.245 322.561 4.395
202509 4.542 324.800 4.670
202512 4.404 324.054 4.539
202603 4.129 330.213 4.176
202606 5.296 333.952 5.296

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Collegium Pharmaceutical (STU:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €19.80 is trading 52.1% below its estimated GF Value™ of €41.34.

Key valuation signals for STU:354:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €41.34 vs. price of €19.80 (52.1% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the STU:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
69GF Score

Get the complete analysis for STU:354

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.80
Price
€41.34
GF Value